Skip to main content
$18.14 -$0.25 (-1.4%)

12:25 PM EST on 11/30/23

Denali Therapeutics Inc (NASDAQ:DNLI)

CAPS Rating: No stars

Current Price $18.14 Mkt Cap $2.5B
Open $18.66 P/E Ratio -19.01
Prev. Close $18.39 Div. (Yield) $0.00 (0.0%)
Daily Range $18.12 - $18.92 Volume 178,399
52-Wk Range $15.45 - $33.31 Avg. Daily Vol. 873,171


How do you think NASDAQ:DNLI will perform against the market?

Add Stock to CAPS Watchlist

All Players

7 Outperform
2 Underperform

All-Star Players

1 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:DNLI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:DNLI are also bullish on:

Fools bearish on NASDAQ:DNLI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about DNLI.


Member Avatar congaslim (39.69) Submitted: 1/23/2023 7:19:10 PM : Outperform Start Price: $29.41 NASDAQ:DNLI Score: -50.68

DNLI should have a strong year with several drugs moving along down the pipeline in 2023.


Member Avatar mdriver78 (65.58) Submitted: 1/22/2020 11:03:08 AM : Outperform Start Price: $20.82 NASDAQ:DNLI Score: -59.15

Hope just got a little brighter for those who have Parkinson’s disease. Researchers indicate a signaling protein known as leucine-rich repeat kinase (LRRK2) is a key factor influencing the development of Parkinson’s disease.

High levels of LRRK2 activation are associated with malfunction of lysosomes, the “garbage collectors” in our brain cells. Some people have an overactive variant of the gene for this molecule.
And they also have an increased risk for developing this neurodegenerative disease.

DNLI) is making great progress in attacking this particular target as a way to treat Parkinson’s. The company has two different LRRK2-blocking drugs in clinical trials and recently updated investors on its progress.

One of the company’s therapies, DNL201, showed huge potential in patients by reducing biomarkers for LRRK2 by over 50% while showing no serious safety issues.

Denali’s second Parkinson’s drug, DNL151, showed early results in over 150 patients of a similar makeup — greater than 50% change — and dose-dependent reductions in lysosomal biomarkers as measured via urinalysis.

The company plans to move both drugs into Phase 2/3 clinical trials by the middle of 2020.

The market loved this news when it was released last week, driving DNLI shares up by some 30% in a single trading session.
But I suspect there’s much more to come beyond our current 41% gain in this brain health biotech. The company expects data to read out from its ALS trials by mid-2020, and its Alzheimer’s clinical trial is now fully enrolled.

Positive data from either of these programs would be a huge mover for DNLI shares, and the company has the potential to be worth thousands of percent more over time as it executes on its clinical pipeline.

What I like about Denali’s Alzheimer’s program is its unique approach to dealing with the disease.

We’ve seen huge high-profile drug trial failures in the Alzheimer’s space. Biogen Inc. recently tried to salvage a program that was discontinued in Phase 3 with an FDA submission for high-dose patients.

But high doses of Biogen’s drugs also meant high side effects.
Biogen’s drug, as well as many others, is based on what was the mainstream theory of this disease and repeated failures strongly suggested the theory was wrong.

Denali’s approach, however, is to attack inflammatory pathways in brain cells that lead to cell death. This concept may prove to have far more value, and if the company demonstrates this via clinical data, its own market value will rise.


Find the members with the highest scoring picks in DNLI.

Score Leader


Biotoday (42.93) Score: +220.89

Collaborations with Takeda, Sanofi, and AbbVie.

Member Name Member
Call Time
Score Commentary
motleyfool3 35.57 9/23/2019 Underperform 5Y $18.07 +2.82% +52.63% +49.81 0 Comment
TheGreatSatan 99.44 7/31/2018 Underperform 5Y $12.44 +49.36% +61.72% +12.36 0 Comment
congaslim 39.69 1/24/2023 Outperform 1Y $29.41 -36.82% +13.85% -50.68 1 Comment
jeepdrew222 38.11 12/22/2017 Outperform 5Y $16.20 +14.69% +69.98% -55.29 0 Comment
mdriver78 65.58 2/27/2020 Outperform 5Y $20.82 -10.76% +48.39% -59.15 1 Comment
BOBBYLDc 60.94 6/7/2018 Outperform 5Y $18.76 -0.96% +63.88% -64.84 0 Comment
TMFjimhalley < 20 11/9/2020 Outperform 5Y $54.55 -65.94% +24.77% -90.71 0 Comment
TMFSaintCroix 84.12 4/11/2019 4/6/2020 Outperform 5Y $28.22 -34.16% +57.23% -91.39 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. quinpeung 34.78 11/23/2020 Outperform 5Y $63.08 -70.55% +27.11% -97.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DNLI.